您的位置：山东大学 -> 科技期刊社 -> 《山东大学学报（医学版）》

山东大学学报（医学版） ›› 2015, Vol. 53 ›› Issue (2): 1-5.doi: 10.6040/j.issn.1671-7554.0.2014.639

• 基础医学 •    下一篇

血脂康对实验性自身免疫性神经炎的治疗潜能

张蓬1, 岳龙涛2, 李亨1, 张民1, 王聪聪1, 段瑞生1, 窦迎春3   

  1. 1. 山东大学附属千佛山医院神经内科, 山东 济南 250014;
    2. 山东大学附属千佛山医院中心实验室, 山东 济南 250014;
    3. 山东中医药大学基础医学院, 山东 济南 250355
  • 收稿日期:2014-09-23 出版日期:2015-02-10 发布日期:2015-02-10
  • 通讯作者: 窦迎春. E-mail:douyingchun01@163.com;段瑞生. E-mail:ruisheng_duan@yahoo.com E-mail:douyingchun01@163.com;ruisheng_duan@yahoo.com
  • 基金资助:
    山东省自然科学基金(ZR2010HM119)

Therapeutic effects of traditional Chinese medicine Xuezhikang on experimental autoimmune neuritis

ZHANG Peng1, YUE Longtao2, LI Heng1, ZHANG Min1, WANG Congcong1, DUAN Ruisheng1, DOU Yingchun3   

  1. 1. Department of Neurology, Shandong Provincial Qianfoshan Hospital, Shandong University, Jinan 250014, Shandong, China;
    2. Central Laboratory, Shandong Provincial Qianfoshan Hospital, Shandong University, Jinan 250014, Shandong, China;
    3. College of Basic Medical Sciences, Shandong University of Traditional Chinese Medicine, Jinan 250355, Shandong, China
  • Received:2014-09-23 Online:2015-02-10 Published:2015-02-10

PDF (PC)

810

摘要： 目的 探讨传统中药血脂康对实验性自身免疫性神经炎(EAN)大鼠的治疗潜能及免疫调节机制.方法 应用周围髓鞘蛋白(P0)抗原180~199肽段免疫雌性Lewis大鼠建立EAN模型,将15只EAN大鼠随机、平均分为大剂量治疗组[1 000 mg/(kg·d)]、小剂量治疗组[200 mg/(kg·d)]和对照组(每组n=5),采用双盲法每日观察大鼠临床症状并评分;流式细胞技术检测淋巴结单个核细胞悬液细胞因子TNF-α、IFN-γ、IL-10和 IL-17的分泌情况以及调节性T细胞在淋巴结单个核细胞及CD4+T细胞中所占百分比.结果 与对照组相比,血脂康大、小剂量治疗组的临床评分均降低,TNF-α的分泌均减少(P均< 0.01);IL-10的分泌量均明显受到抑制(P<0.001和P<0.01);大剂量治疗组IL-17的分泌较对照组减少(P<0.01).与对照组相比,小剂量治疗组CD4+CD25+ T细胞占淋巴结单个核细胞的百分比、大剂量治疗组CD4+CD25+ T细胞和CD4+Foxp3+ T细胞占淋巴结单个核细胞及CD4+T细胞的比例均明显降低(P均<0.05).与对照组比较,大剂量治疗组CD4+CD25+Foxp3+Treg占淋巴结单个核细胞及CD4+T细胞的比例降低(P值分别为0.075和0.066).结论 血脂康通过抑制TNF-α、IL-10和 IL-17细胞因子产生,缓解了EAN大鼠病情,但同时抑制了CD4+T细胞向Treg的分化.

关键词: 血脂康, 实验性自身免疫性神经炎, 细胞因子, 格林巴利综合征, 调节性T细胞

Abstract: Objective To investigate the effect of traditional Chinese medicine Xuezhikang on experimental autoimmune neuritis (EAN) rats. Methods EAN model was established by immunization of Lewis rats with P0 peptide 180-199. Fifteen rats were randomly divided into three groups(n=5 in each group), i.e., control group, low-dose group and high-dose group, in which Xuezhikang was administrated orally by gavage daily at a dose of 200 mg/(kg·d) and 1 000 mg/(kg·d). The levels of intracellular cytokines TNF-α, IFN-γ, IL-10 and IL-17 as well as Treg cells among MNCs and CD4+ T cells from lymph nodes were analyzed by flow cytometry. Results Compared with control group, Xuezhikang treatment at both high and low dose successfully ameliorated EAN on day 16 post immunization(the peak of clinical symptoms). Xuezhikang, at doses of 1 000 and 200 mg/(kg·d), inhibited the secretion of TNF-α (P<0.01), as well as IL-10 (P<0.001 and P< 0.01). Lower IL-17 level was found in high-dose group compared with that in control group (P<0.01). Compared with control group, the percentage of CD4+CD25+ T cells among lymph node mononuclear cells in low-dose group, as well as the percentages of CD4+CD25+ T cells and CD4+Foxp3+ T cells among lymph node mononuclear cells and CD4+ T cells in high-dose group all decreased obviously(P<0.05). The percentages of CD4+CD25+ Foxp3+ T cells among lymph node mononuclear cells and CD4+ T cells in high-dose group were lower than those in control group(P=0.075 and 0.066). Conclusion Xuezhikang can ameliorate EAN bydown-regulating the production of cytokines TNF-α, IL-10 and IL-17, but at the same time it suppresses the differentiation of CD4+T cells to Treg cells.

Key words: Cytokine, T regulatory cell, Xuezhikang, syndrome, Experimental autoimmune neuritis, Guillain-Barré

中图分类号: 

  • R745.43
[1] Xia RH, Yosef N, Ubogu EE. Clinical, electrophysiological and pathologic correlations in a severe murine experimental autoimmune neuritis model of Guillain-Barre syndrome[J]. J Neuroimmunol, 2010, 219(1-2):54-63.
[2] Li H, Li XL, Zhang M, et al. Berberine ameliorates experimental autoimmune neuritis by suppressing both cellular and humoral immunity[J]. Scand J Immunol, 2014, 79(1):12-19.
[3] Li XL, Dou YC, Liu Y, et al. Atorvastatin ameliorates experimental autoimmune neuritis by decreased Th1/Th17 cytokines and up-regulated T regulatory cells[J]. Cell Immunol, 2011, 271(2):455-461.
[4] Yang CW, Mousa SA. The effect of red yeast rice (Monascus purpureus) in dyslipidemia and other disorders[J]. Complement Ther Med, 2012, 20(6):466-474.
[5] Nicholls SJ, Pisaniello AD, Kataoka Y, et al. Lipid pharmacotherapy for treatment of atherosclerosis[J]. Expert Opin Pharmacother, 2014, 15(8):1119-1125.
[6] Zhang X, Jin J, Peng X, et al. Simvastatin inhibits IL-17 secretion by targeting multiple IL-17-regulatory cytokines and by inhibiting the expression of IL-17 transcription factor RORC in CD4+ lymphocytes[J]. J Immunol, 2008, 180(10):6988-6996.
[7] Zhang X, Tao Y, Wang J, et al. Simvastatin inhibits secretion of Th17-polarizing cytokines and antigen presentation by DCs in patients with relapsing remitting multiple sclerosis[J]. Eur J Immunol, 2013, 43(1):281-289.
[8] Tang TT, Song Y, Ding YJ, et al. Atorvastatin upregulates regulatory T cells and reduces clinical disease activity in patients with rheumatoid arthritis[J]. J Lipid Res, 2011, 52(5):1023-1032.
[9] Xiao Y, Liang L, Pan Y, et al. Inhibitory effects of simvastatin on migration and invasion of rheumatoid fibroblast-like synoviocytes by preventing geranylgeranylation of RhoA[J]. Rheumatol Int, 2013, 33(2):389-399.
[10] 王慧力, 唐长华, 王芳. 血脂康不良反应[J]. 中国误诊学杂志, 2010, 10(6):1496-1501.
[11] 蓝晓红, 周永刚. 血脂康胶囊致横纹肌溶解症1例[J]. 中国药物警戒, 2010, 7(4):255-256.
[12] Zhang HL, Zheng XY, Zhu J. Th1/Th2/Th17/Treg cytokines in Guillain-Barre syndrome and experimental autoimmune neuritis[J]. Cytokine Growth Factor Rev, 2013, 24(5):443-453.
[13] Deng H, Yang X, Jin T, et al. The role of IL-12 and TNF-alpha in AIDP and AMAN[J]. Eur J Neurol, 2008, 15(10):1100-1105.
[14] Bao L, Lindgren JU, Zhu Y, et al. Exogenous soluble tumor necrosis factor receptor type I ameliorates murine experimental autoimmune neuritis[J]. Neurobiol Dis, 2003, 12(1):73-81.
[15] Sabat R, Grutz G, Warszawska K, et al. Biology of interleukin-10[J]. Cytokine Growth Factor Rev, 2010, 21(5):331-344.
[16] O'Garra A, Barrat FJ, Castro AG, et al. Strategies for use of IL-10 or its antagonists in human disease[J]. Immunol Rev, 2008, 223:114-131.
[17] Myhr KM, Vagnes KS, Maroy TH, et al. Interleukin-10 promoter polymorphisms in patients with Guillain-Barre syndrome[J]. J Neuroimmunol, 2003, 139(1-2):81-83.
[18] Doreau A, Belot A, Bastid J, et al. Interleukin 17 acts in synergy with B cell-activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus[J]. Nat Immunol, 2009, 10(7):778-785.
[19] Li S, Yu M, Li H, et al. IL-17 and IL-22 in cerebrospinal fluid and plasma are elevated in Guillain-Barre syndrome[J]. Mediators Inflamm, 2012, 2012:260473. doi: 10.1155/2012/260473.
[20] Hofstetter HH, Ibrahim SM, Koczan D, et al. Therapeutic efficacy of IL-17 neutralization in murine experimental autoimmune encephalomyelitis[J]. Cell Immunol, 2005,237(2):123-130.
[21] Reise Sousa C. Dendritic cells in a mature age[J]. Nat Rev Immunol, 2006, 6(6):476-483.
[22] Li XL, Liu Y, Cao LL, et al. Atorvastatin-modified dendritic cells in vitro ameliorate experimental autoimmune myasthenia gravis by up-regulated Treg cells and shifted Th1/Th17 to Th2 cytokines[J]. Mol Cell Neurosci, 2013, 56:85-95.
[1] 张锦涛,董亮. 气道上皮及其源性细胞因子与哮喘:思考与展望[J]. 山东大学学报 (医学版), 2024, 62(5): 1-6.
[2] 田欣鑫,王立俊,李琳,孙正达,刘海燕. CD300c-Ig对小鼠关节损伤的影响及机制[J]. 山东大学学报 (医学版), 2024, 62(2): 29-35.
[3] 吴飞,李清丽,肖振卫. 孟德尔随机化探究细胞因子与慢性肾脏病的因果关系[J]. 山东大学学报 (医学版), 2024, 62(11): 85-95.
[4] 祁少俊,唐延金,张正铎,吴虹,张佳程,秦川,刘锐,高希宝. 补充多种微量元素对高糖饮食大鼠的保护作用[J]. 山东大学学报 (医学版), 2023, 61(7): 19-26.
[5] 王园园,孙云. 合并新型冠状病毒肺炎的维持性血液透析患者死亡危险因素[J]. 山东大学学报 (医学版), 2023, 61(11): 68-73.
[6] 王福立,孙银萍,秦杰,荣建胜. DC-CIK细胞联合EGFR-TKI治疗35例老年晚期EGFR突变肺癌的效果[J]. 山东大学学报 (医学版), 2022, 60(7): 110-117.
[7] 高惠茹,杜甜甜,王允山,杜鲁涛,王传新. 基于单细胞转录组测序数据分析胃癌调节性T细胞特征[J]. 山东大学学报 (医学版), 2022, 60(5): 43-49.
[8] 李华玉,时萧寒,张新蕊,李峰. 203例胶质瘤患者睡眠障碍与炎症细胞因子的关联分析[J]. 山东大学学报 (医学版), 2022, 60(12): 26-30.
[9] 张阿敏,李国盛,李福海. 儿童支原体大叶性肺炎肺泡灌洗液细胞因子与局部炎症的相关性[J]. 山东大学学报 (医学版), 2022, 60(11): 82-88.
[10] 葛少华,丁田,刘红蕊. 2型免疫在组织修复中的作用及调控机制[J]. 山东大学学报 (医学版), 2021, 59(9): 51-56.
[11] 周溪,黄霂晗,任玉洁,邱洋. 新型冠状病毒感染与天然免疫及炎症反应[J]. 山东大学学报 (医学版), 2021, 59(5): 15-21.
[12] 李湘青,殷欣,赵雪莲,赵培庆. NK细胞亚群CD56bright在帕金森患者外周血中的表达及临床意义[J]. 山东大学学报 (医学版), 2021, 59(2): 34-40.
[13] 鞠秀丽. 间充质干细胞治疗新型冠状病毒肺炎的潜在机制和研究进展[J]. 山东大学学报 (医学版), 2020, 58(3): 32-37.
[14] 李雪,李栋,时庆,周盼盼,鞠秀丽. Helios在儿童急性淋巴细胞性白血病调节性T细胞中的表达及功能[J]. 山东大学学报（医学版）, 2017, 55(4): 76-81.
[15] 余桂芳,陈树娣,陈雪竹,侯开连,梁敏. miR-916a调控SOCS6促进HBx-HepG2细胞生长[J]. 山东大学学报（医学版）, 2016, 54(12): 14-19.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
版权所有 © 2018 《山东大学学报(医学版)》编辑部　
地址:山东大学科技期刊社（济南市历城区山大南路27号山东大学中心校区明德楼B座721室） 电话: 0531-88366918 E-mail: xbyxb@sdu.edu.cn
本系统由北京玛格泰克科技发展有限公司设计开发